MEDCL MedinCell SA

Medincell to Join the Euronext SBF 120 Index

Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index.

Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a recognition of our strength and performance. This milestone enhances our attractiveness to new French and international institutional investors and will increase our visibility among financial analysts and the media. This distinction should lead to greater trading volume in our shares. I would like to thank Medincell's employees - who are all shareholders, and all our individual and institutional shareholders for their confidence. This new step is the result of their ongoing support.”

The composition of the SBF 120 and CAC Mid 60 is decided by Euronext's Scientific Council for Indices on the basis of the market capitalizations and liquidity (trading volume) of companies listed on Euronext Paris.

Medincell's inclusion in the index will be effective from 20 December, after market close.

The SBF 120 index includes the following companies listed on Euronext Paris:

  • CAC 40: the 40 largest market capitalizations

  • CAC Next 20: The next 20 largest stocks following the CAC 40. Together, the CAC 40 and CAC Next 20 form the CAC Large 60.

  • CAC Mid 60: the 60 largest capitalizations on the first and second markets (excluding the CAC Large 60)

List of companies in the SBF 120 index:

List of companies in the CAC Mid 60 index:

Euronext press release:

EN
12/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedinCell SA

Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Medincell : A solid foundation for new ambitions

In the context of the ODDO BHF Forum, we had the opportunity to get an update on management's short- and medium-term ambitions. The next few months are set to be transformative for Medincell, with 1/ the ramp-up in sales of Uzedy, 2/ the launch of Olanzapine LAI, considered by its partner Teva to be a blockbuster, and 3/ the entry into clinical trials of its first drug candidate from its partnership with Abbvie. These commercial, regulatory and clinical milestones will likely support the share p...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Medincell : Une base solide pour de nouvelles ambitions

Dans le cadre du Forum ODDO BHF, nous avons eu l’occasion de revenir sur les ambitions à court et moyen termes du management. Aussi, les prochains mois de Medincell devraient être transformants avec 1/ la montée en puissance des ventes d’Uzedy, 2/ le lancement d’Olanzapine LAI considéré par son partenaire Teva comme un blockbuster et 3/ l’entrée en clinique de son 1er candidat médicament venant de son partenariat avec Abbvie. Ces milestones commerciaux, réglementaires et cliniques devraient perm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch